Metrics as of 10/15/2026, 11:45 AM (Berlin time), refresh in progress.
Capricor Therapeutics Stock
Capricor Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Linda Marbán
- Employees
- 231
- Market cap
- $382 M
- IPO
- 13/02/2007
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases…
Capricor Therapeutics stock: price history
1D
-4.2%
1W
-18.6%
1M
-25.2%
6M
-81.2%
YTD
-77.2%
1Y
-1.6%
2Y
-66.3%
5Y
+66.4%
10Y
-80.7%
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~17% weaker price swings than usual
Capricor Therapeutics stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
Capricor Therapeutics is a clinical-stage biotechnology company headquartered in San Diego focused on developing cell- and exosome-based therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company's pipeline includes the drug candidates CAP-1002 and CAP-2003, as well as an exosome-based vaccine. As the company is currently in the clinical phase, no commercial revenues from drug sales have been generated to date.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Strong
- Moat
- Wide
- Moat type
- Brand / IP
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Capricor Therapeutics
Analyst assessment of Capricor Therapeutics
PRICE TARGET LOW
US$3.50
CONSENSUS
US$12.70
MEDIAN
US$7.00
PRICE TARGET HIGH
US$25.00
0
STRONG BUY
8
BUY
2
HOLD
0
SELL
0
STRONG SELL
10
TOTAL · Buy
As of: 14/09/2026
Capricor Therapeutics stock metrics
P/E
-2.69
P/B
1.55
EV/EBITDA
0.38
RETURN ON EQUITY
-16.5%
NET MARGIN
0.0%
DEBT/EQUITY
0.37
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
90.9%
FLOAT SHARES
52,652,655
AVG. DAILY VOLUME (30D)
3,494,561
Insider transactions (SEC)
Krasney Karen
Krasney Karen
Bergmann Anthony
Bergmann Anthony
Krasney Karen
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -4.2%
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Capricor Therapeutics stock
What does Capricor Therapeutics do?
Capricor Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Linda Marbán, the company employs around 231 people.
The IPO was on 13/02/2007; the stock trades on NASDAQ under the ticker CAPR.
What do analysts say about Capricor Therapeutics stock?
10 analysts rate the stock, the consensus is Buy (as of 14/09/2026).
The average price target is US$12.70, ranging from US$3.50 to US$25.00, with a median of US$7.00.
This is an external assessment, not a statement by Market Jury.
When does Capricor Therapeutics report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly -17% stronger than usual.
Does Capricor Therapeutics pay a dividend?
No, Capricor Therapeutics currently does not pay a dividend.
Which stocks are comparable to Capricor Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Capricor Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Capricor Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.